Latest Conference Articles

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.

The microbiota-based therapy had a favorable safety profile and demonstrated response-driven prolongation of survival in this patient population.

Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.

The 600-mg RP2D of Ziftomenib in combination with venetoclax/azacitidine displayed high response rates in NPM1-mutated AML.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Gerhard Hildebrandt, MD, FACP, and Muhamed Baljevic, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in acute leukemia and multiple myeloma presented during the 2025 ASH Annual Meeting & Exposition.

Talquetamab plus teclistamab produced a high ORR and CR or better rate in relapsed/refracotry multiple myeloma with true extramedullary disease.

Linvoseltamab monotherapy produced responses and was safe in newly diagnosed multiple myeloma.

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Subcutaneous cevostamab demonstrated activity and safety in patients with multiple myeloma who had received a median of 5 prior lines of therapy.

Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib yields superior overall response rates and promising progression-free survival compared with ibrutinib in chronic lymphocytic leukemia.

Adding epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in patients with relapsed/refractory follicular lymphoma.

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.